{"entity": "researcher", "timestamp": "2026-08-20T21:31:14.828Z", "family": "Brunnstr\u00f6m", "given": "Hans", "initials": "H", "orcid": "0000-0001-7402-138X", "affiliations": ["Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.", "Department of Genetics and Pathology, Laboratory Medicine Region Sk\u00e5ne, Lund, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b51d0768d1a4c31bba8cf898f962a09.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b51d0768d1a4c31bba8cf898f962a09"}}, "publications": [{"entity": "publication", "iuid": "e592453711d34172ba82290c80b6efd8", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/e592453711d34172ba82290c80b6efd8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/e592453711d34172ba82290c80b6efd8"}}, "title": "Fibroblast subsets in non-small cell lung cancer: Associations with survival, mutations, and immune features.", "authors": [{"family": "Pellinen", "given": "Teijo", "initials": "T", "orcid": "0000-0001-9652-7373", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8e73595c0cc64a68a59cd95772784859.json"}}, {"family": "Paavolainen", "given": "Lassi", "initials": "L"}, {"family": "Mart\u00edn-Bernab\u00e9", "given": "Alfonso", "initials": "A"}, {"family": "Papatella Araujo", "given": "Renata", "initials": "R"}, {"family": "Strell", "given": "Carina", "initials": "C", "orcid": "0000-0002-3783-7256", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f288539ea7eb406480c84ec1a5605a91.json"}}, {"family": "Mezheyeuski", "given": "Artur", "initials": "A"}, {"family": "Backman", "given": "Max", "initials": "M"}, {"family": "La Fleur", "given": "Linnea", "initials": "L"}, {"family": "Br\u00fcck", "given": "Oscar", "initials": "O"}, {"family": "Sj\u00f6lund", "given": "Jonas", "initials": "J"}, {"family": "Holmberg", "given": "Erik", "initials": "E", "orcid": "0000-0001-5107-4550", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/cad9bec668814f47bce74228eef5e7e0.json"}}, {"family": "V\u00e4lim\u00e4ki", "given": "Katja", "initials": "K"}, {"family": "Brunnstr\u00f6m", "given": "Hans", "initials": "H", "orcid": "0000-0001-7402-138X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b51d0768d1a4c31bba8cf898f962a09.json"}}, {"family": "Botling", "given": "Johan", "initials": "J"}, {"family": "Moreno-Ruiz", "given": "Pablo", "initials": "P"}, {"family": "Kallioniemi", "given": "Olli", "initials": "O"}, {"family": "Micke", "given": "Patrick", "initials": "P"}, {"family": "\u00d6stman", "given": "Arne", "initials": "A"}], "type": "journal article", "published": "2023-01-10", "journal": {"title": "J. Natl. Cancer Inst.", "issn": "1460-2105", "volume": "115", "issue": "1", "pages": "71-82", "issn-l": "0027-8874"}, "abstract": "Cancer-associated fibroblasts (CAFs) are molecularly heterogeneous mesenchymal cells that interact with malignant cells and immune cells and confer anti- and protumorigenic functions. Prior in situ profiling studies of human CAFs have largely relied on scoring single markers, thus presenting a limited view of their molecular complexity. Our objective was to study the complex spatial tumor microenvironment of non-small cell lung cancer (NSCLC) with multiple CAF biomarkers, identify novel CAF subsets, and explore their associations with patient outcome.\n\nMultiplex fluorescence immunohistochemistry was employed to spatially profile the CAF landscape in 2 population-based NSCLC cohorts (n = 636) using antibodies against 4 fibroblast markers: platelet-derived growth factor receptor-alpha (PDGFRA) and -beta (PDGFRB), fibroblast activation protein (FAP), and alpha-smooth muscle actin (\u03b1SMA). The CAF subsets were analyzed for their correlations with mutations, immune characteristics, and clinical variables as well as overall survival.\n\nTwo CAF subsets, CAF7 (PDGFRA-/PDGFRB+/FAP+/\u03b1SMA+) and CAF13 (PDGFRA+/PDGFRB+/FAP-/\u03b1SMA+), showed statistically significant but opposite associations with tumor histology, driver mutations (tumor protein p53 [TP53] and epidermal growth factor receptor [EGFR]), immune features (programmed death-ligand 1 and CD163), and prognosis. In patients with early stage tumors (pathological tumor-node-metastasis IA-IB), CAF7 and CAF13 acted as independent prognostic factors.\n\nMultimarker-defined CAF subsets were identified through high-content spatial profiling. The robust associations of CAFs with driver mutations, immune features, and outcome suggest CAFs as essential factors in NSCLC progression and warrant further studies to explore their potential as biomarkers or therapeutic targets. This study also highlights multiplex fluorescence immunohistochemistry-based CAF profiling as a powerful tool for the discovery of clinically relevant CAF subsets.", "doi": "10.1093/jnci/djac178", "pmid": "36083003", "labels": [], "xrefs": [{"db": "pii", "key": "6694853"}], "notes": [], "created": "2026-08-20T09:42:16.530Z", "modified": "2026-08-20T09:42:16.675Z"}, {"entity": "publication", "iuid": "c9f9cc2051344e69bdd4b7bbd9ca6804", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c9f9cc2051344e69bdd4b7bbd9ca6804.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c9f9cc2051344e69bdd4b7bbd9ca6804"}}, "title": "Comprehensive analysis of RNA binding motif protein 3 (RBM3) in non-small cell lung cancer.", "authors": [{"family": "Salomonsson", "given": "Annette", "initials": "A"}, {"family": "Micke", "given": "Patrick", "initials": "P"}, {"family": "Mattsson", "given": "Johanna S M", "initials": "JSM"}, {"family": "La Fleur", "given": "Linnea", "initials": "L"}, {"family": "Isaksson", "given": "Johan", "initials": "J"}, {"family": "J\u00f6nsson", "given": "Mats", "initials": "M"}, {"family": "Nodin", "given": "Bj\u00f6rn", "initials": "B"}, {"family": "Botling", "given": "Johan", "initials": "J"}, {"family": "Uhl\u00e9n", "given": "Mathias", "initials": "M"}, {"family": "Jirstr\u00f6m", "given": "Karin", "initials": "K"}, {"family": "Staaf", "given": "Johan", "initials": "J", "orcid": "0000-0001-5254-5115", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3c7e552718d34d09a9a11aa54e90e37c.json"}}, {"family": "Planck", "given": "Maria", "initials": "M"}, {"family": "Brunnstr\u00f6m", "given": "Hans", "initials": "H", "orcid": "0000-0001-7402-138X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b51d0768d1a4c31bba8cf898f962a09.json"}}], "type": "journal article", "published": "2020-08-00", "journal": {"title": "Cancer Med", "issn": "2045-7634", "volume": "9", "issue": "15", "pages": "5609-5619", "issn-l": "2045-7634"}, "abstract": "High expression of the RNA-binding motif protein 3 (RBM3) correlates with improved prognosis in several major types of cancer. The aim of the present study was to examine the prognostic value of RBM3 protein and mRNA expression in non-small cell lung cancer (NSCLC).\n\nImmunohistochemical expression of RBM3 was evaluated in surgically treated NSCLC from two independent patient populations (n = 213 and n = 306). Staining patterns were correlated with clinicopathological parameters, overall survival (OS), and recurrence-free interval (RFI). Cases with high nuclear RBM3 protein expression had a prolonged 5-year OS in both cohorts when analyzing adenocarcinomas separately (P = .02 and P = .01). RBM3 remained an independent prognostic factor for OS in multivariable analysis of cohort I (HR 0.44, 95% CI 0.21-0.90) and for RFI in cohort II (HR 0.38, 95% CI 0.22-0.74). In squamous cell carcinoma, there was instead an insignificant association to poor prognosis. Also, the expression levels of RBM3 mRNA were investigated in 2087 lung adenocarcinomas and 899 squamous cell carcinomas assembled from 13 and 8 public gene expression microarray datasets, respectively. The RBM3 mRNA levels were not clearly associated with patient outcome in either adenocarcinomas or squamous cell carcinomas.\n\nThe results from this study support that high protein expression of RBM3 is linked to improved outcome in lung adenocarcinoma.", "doi": "10.1002/cam4.3149", "pmid": "32491279", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7402820"}], "notes": [], "created": "2026-08-20T06:30:42.753Z", "modified": "2026-08-20T06:30:42.830Z"}]}